Theriva Biologics (TOVX)
NYSE MKT:TOVX
Holding TOVX?
Track your performance easily

Theriva Biologics (TOVX) Income Statement

1,015 Followers

Theriva Biologics Income Statement

Last quarter (Q2 2024), Theriva Biologics's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Theriva Biologics's net income was $-8.30M. See Theriva Biologics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 24.31M$ 21.43M$ 21.58M$ -14.27M$ 10.16M$ 15.66M
Operating Income
$ -24.31M$ -21.43M$ -21.58M$ -14.27M$ -10.16M$ -15.66M
Net Non Operating Interest Income Expense
$ 1.09M$ 1.44M$ 512.00K$ 6.00K$ 44.00K$ 283.00K
Other Income Expense
$ -525.00K$ 3.00K$ 1.62M---
Pretax Income
$ -23.22M$ -19.99M$ -21.11M$ -14.27M$ -10.12M$ -15.38M
Tax Provision
$ -951.00K$ -1.64M$ -1.43M$ -932.00K--
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -22.29M$ -18.35M$ -20.02M$ -23.19M$ -12.56M$ -16.08M
Basic EPS
$ -1.24$ -1.14$ -1.31$ -0.19$ -0.66$ -0.98
Diluted EPS
$ -1.24$ -1.14$ -1.31$ -0.19$ -0.66$ -0.98
Basic Average Shares
$ 70.68M$ 16.11M$ 15.33M$ 121.88M$ 19.01M$ 16.44M
Diluted Average Shares
$ 70.68M$ 16.11M$ 15.33M$ 121.88M$ 19.01M$ 16.44M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 24.31M$ 21.43M$ 21.58M$ -14.27M$ 10.16M$ 15.66M
Net Income From Continuing And Discontinued Operation
$ -22.29M$ -18.35M$ -19.68M$ -14.27M$ -10.04M$ -15.30M
Normalized Income
$ -20.63M$ -22.29M--$ -10.04M$ -15.30M
Interest Expense
------
EBIT
$ -23.51M$ -21.43M$ -21.11M$ -14.27M$ -10.16M$ -15.66M
EBITDA
$ -23.36M$ -21.30M$ -21.02M$ -14.19M$ -9.96M$ -15.42M
Currency in USD

Theriva Biologics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis